fashion -WSS

fashion

author：fashion 2025-10-01 18:45:49 - browse：7

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

WSS

Duchenne breakthrough therapy leaves behind pioneering families

In age of alternative facts, a scholarly course on calling out crap

Hospital at home shows how to bring innovation to health care

Kellogg’s is going to war over Mexico’s nutrition label rules

Health officials lay out plans to cope with respiratory virus season

PBMs are inflating the cost of generic drugs. They must be reined in

explore

fashion

entertainment

Novavax promises a turnaround & Lilly roils the obesity market

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

In age of alternative facts, a scholarly course on calling out crap

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Activists slam private health insurers over coverage restrictions

Health officials lay out plans to cope with respiratory virus season

DIEP, the 'gold standard' of breast reconstruction, is under threat

How the drug

23andMe had bad news about my health. I wish a person had delivered it

FDA greenlights medical device to combat bladder issues

focus

ChatGPT in medicine: STAT answers readers' burning questions

DIEP, the 'gold standard' of breast reconstruction, is under threat

Anesthesiologist group: stop taking Ozempic before surgery

Medical leaders decry Supreme Court decision on affirmative action

CDC says it’s too soon to assess risk posed by Covid subvariant

Can U.S. cancer drug shortages be fixed?

knowledge

explore

knowledge

knowledge